These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 22057732

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI, Park S, Kim JH, Kim HR, Kim M, Moon K, Seo J, Lee GW.
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
    Jurczak W, Ochrem B, Giza A, Zimowska-Curyło D, Górecki T, Boguradzki P, Knopińska-Posłuszny W, Stella-Hołowiecka B, Walewski J, Joks M, Wróbel T, Zaucha JM.
    Pol Arch Med Wewn; 2015 Aug; 125(10):741-8. PubMed ID: 26334344
    [Abstract] [Full Text] [Related]

  • 28. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
    Chae YS, Shin H, Sohn SK, Lee SJ, Moon JH, Kang BW, Kim JG, Yang DH, Lee JJ, Park TI.
    Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Li X, Huang H, Xu B, Guo H, Lin Y, Ye S, Yi J, Li W, Wu X, Wang W, Zhan H, Xie D, Peng J, Cao Y, Pu X, Guo C, Hong H, Wang Z, Fang X, Zhou Y, Lin S, Liu Q, Lin T.
    Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
    [Abstract] [Full Text] [Related]

  • 31. Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Cho MC, Chung Y, Jang S, Park CJ, Chi HS, Huh J, Suh C, Shim H.
    Medicine (Baltimore); 2018 Nov; 97(45):e13046. PubMed ID: 30407302
    [Abstract] [Full Text] [Related]

  • 32. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
    Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H, Kahl BS, Advani RH, Horning SJ.
    Br J Haematol; 2015 Sep; 170(5):679-86. PubMed ID: 25974212
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.
    J Clin Oncol; 2017 Nov 01; 35(31):3538-3546. PubMed ID: 28862883
    [Abstract] [Full Text] [Related]

  • 35. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V, Prka Ž, Lucijanić M, Mitrović Z, Piršić M, Jakšić O, Ajduković R, Kušec R.
    Croat Med J; 2017 Feb 28; 58(1):40-48. PubMed ID: 28252874
    [Abstract] [Full Text] [Related]

  • 36. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
    Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, Flament J, Flowers C, Shi Q, Schmitz N.
    Blood; 2020 Jun 04; 135(23):2041-2048. PubMed ID: 32232482
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
    Sehn LH, Martelli M, Trněný M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, Vitolo U.
    J Hematol Oncol; 2020 Jun 06; 13(1):71. PubMed ID: 32505213
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
    Park JH, Yoon DH, Kim DY, Kim S, Seo S, Jeong Y, Lee SW, Park CS, Huh J, Suh C.
    Ann Hematol; 2014 Oct 06; 93(10):1755-64. PubMed ID: 25027115
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.